SPRB SPRUCE BIOSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1683553 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-90.2%
TTM net income YoY-21.4%
TTM EPS YoY-55.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-7,100.0%
Net margin-6,869.3%
FCF margin-6,821.8%
EBITDA margin-7,096.4%
Returns
ROE-167.9%
ROA-119.1%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets64.8%
Debt / equity0.10x
Current ratio1.54x
Interest coverage-353.48x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.8%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $4.91M | $10.09M | $0 | — |
| R&D expense | $19.52M | $46.42M | $49.43M | $35.20M | $30.70M |
| SG&A expense | $16.99M | $14.64M | $12.65M | $12.09M | $11.37M |
| Operating income | -$36.51M | -$56.15M | -$51.99M | -$47.28M | -$42.07M |
| Interest expense | $90,000 | $307,000 | $483,000 | $420,000 | $345,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$38.97M | -$53.04M | -$47.92M | -$46.18M | -$42.29M |
| EBITDA | -$36.49M | -$56.10M | -$51.92M | -$47.21M | -$42.00M |
| EPS (basic) | -50.83 | -96.40 | -1.24 | -1.96 | -1.81 |
| EPS (diluted) | -50.83 | -96.40 | -1.24 | -1.96 | -1.81 |
| Weighted avg. shares (diluted) | 766,598 | 550,146 | 38.51M | 23.53M | 23.36M |
| Balance sheet | |||||
| Cash & equivalents | $48.91M | $38.79M | $96.37M | $24.73M | $42.96M |
| Short-term investments | — | — | $0 | $54.59M | $46.22M |
| Receivables | — | — | — | $0 | — |
| Current assets | $52.11M | $44.21M | $102.18M | $83.61M | $91.89M |
| PP&E, net | — | — | — | — | $140,000 |
| Total assets | $53.02M | $45.21M | $103.95M | $85.65M | $126.49M |
| Current liabilities | $10.09M | $15.25M | $24.46M | $12.45M | $8.87M |
| Short-term debt | $0 | $1.62M | $1.62M | $1.62M | $0 |
| Long-term debt | $0 | $124,000 | $1.72M | $3.29M | $4.88M |
| Total debt | $0 | $1.75M | $3.34M | $4.92M | $4.88M |
| Total liabilities | $10.51M | $16.39M | $27.44M | $17.16M | $15.12M |
| Shareholders' equity | $42.52M | $28.82M | $76.51M | $68.49M | $111.37M |
| Net debt | -$48.91M | -$37.04M | -$93.03M | -$19.82M | -$38.09M |
| Shares outstanding | 1.37M | 563,042 | 41.03M | 23.60M | 23.49M |
| Cash flow statement | |||||
| Operating cash flow | -$33.33M | -$55.96M | -$33.27M | -$41.68M | -$35.88M |
| Capital expenditure | — | $0 | $7,000 | $8,000 | $93,000 |
| Free cash flow | — | -$55.96M | -$33.28M | -$41.69M | -$35.97M |
| Investing cash flow | — | $0 | $55.78M | $23.69M | -$79.17M |
| Financing cash flow | $43.48M | -$1.62M | $49.14M | -$241,000 | $643,000 |
| Depreciation & amortization | $21,000 | $46,000 | $70,000 | $74,000 | $68,000 |
| Stock-based compensation | $2.57M | $5.35M | $4.62M | $3.63M | $3.96M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.